Related Experiment Videos
Platelet activation in patients with chronic hepatitis C
Hisae Fusegawa1, Koichi Shiraishi, Fusao Ogasawara
1Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan. fusegawa@is.icc.u-tokai.ac.jp
The Tokai Journal of Experimental and Clinical Medicine
|April 26, 2003
Summary
Patients with chronic hepatitis C (CHC) show increased platelet activation, potentially causing low platelet counts. Liver fibrosis severity correlates with this platelet activation in CHC.
Area of Science:
- Hepatology
- Hematology
- Immunology
Background:
- Thrombocytopenia is common in chronic hepatitis C (CHC).
- The mechanisms underlying thrombocytopenia in CHC are not fully understood.
- Platelet activation is a potential contributing factor.
Purpose of the Study:
- To investigate platelet activation in patients with chronic viral liver diseases.
- To elucidate the relationship between platelet activation and liver fibrosis in CHC.
Main Methods:
- Flow cytometry was used to assess platelet activation.
- Evaluated platelet activation markers, including activation-dependent monoclonal antibodies and platelet microparticles (PMP).
- Assessed liver fibrosis using liver biopsies and serological markers (hyaluronate, P-III-P).
Main Results:
- Patients with CHC and liver cirrhosis exhibited significantly decreased platelet counts compared to controls.
- Elevated platelet activation markers (positive MoAbs, PMP) were observed in CHC patients compared to chronic hepatitis B (CHB) patients.
- A significant correlation was found between PMP levels, liver fibrosis markers, and histological scores in CHC patients.
Conclusions:
- Increased platelet activation is present in CHC patients.
- Enhanced platelet activation may contribute to thrombocytopenia in CHC.
- Liver fibrosis appears to play a role in platelet activation in CHC.